Compare SELF & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | TLPH |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 64.7M |
| IPO Year | N/A | 2011 |
| Metric | SELF | TLPH |
|---|---|---|
| Price | $5.08 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 44.2K | ★ 477.7K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | ★ 5.72% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $12,733,279.00 | $28,000.00 |
| Revenue This Year | $1.59 | N/A |
| Revenue Next Year | $1.62 | N/A |
| P/E Ratio | $31.63 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $4.73 | $0.38 |
| 52 Week High | $5.89 | $1.57 |
| Indicator | SELF | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 38.20 |
| Support Level | $5.02 | $0.97 |
| Resistance Level | $5.15 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.86 | 8.56 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.